Blumenfeld Orit, Rosenberg Alina, Reuven Michal, Caspi Inbar, Sharoni Erez, Leviner Dror B
Israel Center for Disease Control, Ministry of Health, Ramat-Gan, Israel.
Internal Medicine Department, Tel Aviv Medical Center, Tel Aviv, Israel.
Infect Prev Pract. 2023 Dec 16;6(1):100334. doi: 10.1016/j.infpip.2023.100334. eCollection 2024 Mar.
We compared the effect of perioperative COVID-19, before and after vaccination, on 30-day mortality after cardiac surgery.
Data was extracted from several national registries. The study period was March 1, 2020-March 31, 2022.
2594 adult patients underwent cardiac surgery before the availability of a universal COVID-19 vaccine. 33 patients were diagnosed with COVID-19 prior to surgery (mean age 58.3±10.0, mean length of time 73.6±60.1 days) and 7 patients were diagnosed with COVID-19 0-14 days after surgery (age 66.4±7.6). These were compared to 4426 patients who underwent cardiac surgery after the availability of a universal vaccine: 469 patients were diagnosed with COVID-19 prior to surgery (age 62.1±10.1, length of time 175.8±158.2) and 32 patients diagnosed with COVID-19 0-14 days after surgery (age 60.8±14.5). In patients diagnosed with COVID-19 prior to surgery, there was no excess 30-day mortality either before or after vaccination (1 (3.0%) vs. 57 (2.2%), respectively, <0.8, and 8 (1.7%) vs. 87 (2.2%), respectively, <0.5). Patients diagnosed with COVID-19 after surgery, but before vaccination, had significantly higher 30-day mortality compared to COVID-19 negative patients (2 (28.6%) vs. 56 (2.2%) respectively, <0.0001). This excess mortality disappeared after universal vaccination (1 (3.1%) vs. 94 (2.1%) respectively, <0.7).
COVID-19, when diagnosed in the early post-operative period, was a risk factor for mortality before available vaccinations, but not after vaccination was widely available. Pre-surgery screening and post-surgical isolation is essential until vaccines are available. This data may be useful for patient management in future respiratory pandemics.
我们比较了围手术期感染新型冠状病毒肺炎(COVID-19)在疫苗接种前后对心脏手术后30天死亡率的影响。
数据取自多个国家登记处。研究时间段为2020年3月1日至2022年3月31日。
在通用COVID-19疫苗可用之前,2594例成年患者接受了心脏手术。33例患者在手术前被诊断为COVID-19(平均年龄58.3±10.0岁,平均时间73.6±60.1天),7例患者在手术后0至14天被诊断为COVID-19(年龄66.4±7.6岁)。将这些患者与4426例在通用疫苗可用后接受心脏手术的患者进行比较:469例患者在手术前被诊断为COVID-19(年龄62.1±10.1岁,时间175.8±158.2天),32例患者在手术后0至14天被诊断为COVID-19(年龄60.8±14.5岁)。在手术前被诊断为COVID-19的患者中,疫苗接种前后30天死亡率均无过高情况(分别为1例(3.0%)对57例(2.2%),<0.8;8例(1.7%)对87例(2.2%),<0.5)。与COVID-19阴性患者相比,在手术后但疫苗接种前被诊断为COVID-19的患者30天死亡率显著更高(分别为2例(28.6%)对56例(2.2%),<0.0001)。在通用疫苗接种后,这种过高的死亡率消失了(分别为1例(3.1%)对94例(2.1%),<0.7)。
在术后早期被诊断出的COVID-19,在疫苗可用之前是死亡风险因素,但在疫苗广泛可用之后则不是。在疫苗可用之前,术前筛查和术后隔离至关重要。这些数据可能对未来呼吸道大流行中的患者管理有用。